In murine models bearing breast carcinomas engineered to express a defined neoantigen (rat-erbB2), spontaneous tumor rejection occurred in MHC-II–restricted settings and depended on CD4+ T cells, B cells, and antigen-specific antibodies. The gene discussed is CD4; the disease is neoplasm.